Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HDAC4 | P56524 | 3/20 | 0.53 |
| ▸ | GPR119 | Q8TDV5 | 3/20 | 0.47 |
| ▸ | GRM5 | P41594 | 1/20 | 0.45 |
| ▸ | CKS1B | P61024 | 2/20 | 0.45 |
| ▸ | SKP1 | P63208 | 2/20 | 0.45 |
| ▸ | SKP2 | Q13309 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 4/20 | 0.43 |
| ▸ | HDAC8 | Q9BY41 | 2/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HPGDS | O60760 | 1/20 | 0.43 |
| ▸ | GBA1 | P04062 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL513325 | 0.88 | KCNH2 (0.49) | HDAC4GRM5KMT2A | |
| SCHEMBL513744 | 0.84 | GBA1 (0.51) | HDAC4GPR119GRM5GBA1MAPT | |
| SCHEMBL514962 | 0.81 | GPR119 (0.46) | HDAC4GPR119GRM5CKS1BSKP1 | |
| SCHEMBL513293 | 0.81 | GRM5 (0.46) | HDAC4GPR119GRM5KMT2ASCD5 | |
| SCHEMBL514361 | 0.78 | GRM5 (0.41) | HDAC4GPR119GRM5KMT2ASCD5 | |
| SCHEMBL17100788 | 0.78 | MAPT (0.57) | HDAC4GPR119CKS1BSKP1SKP2 | |
| SCHEMBL513733 | 0.78 | CKS1B (0.44) | HDAC4GPR119GRM5CKS1BSKP1 | |
| SCHEMBL513734 | 0.78 | CKS1B (0.44) | HDAC4GPR119GRM5CKS1BSKP1 | |
| SCHEMBL18280165 | 0.77 | USP30 (0.47) | GPR119GRM5CKS1BSKP1SKP2 | |
| SCHEMBL1473227 | 0.76 | GPR119 (0.51) | GPR119GRM5CKS1BSKP1SKP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477981-A1 | HETEROCYCLIC MGLU5 ANTAGONISTS | Recordati Ireland Limited (IE) | 2012-07-25 | — | — | EP | disclosed |
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | RECORDATI IRELAND LIMITED (IE) | 2012-02-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120028931-A1 | HETEROCYCLIC M-GLU5 ANTAGONISTS | OPRM1, GRM5, OPRD1 | HDAC4 2754/4885GPR119 674/4885GRM5 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.